Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

C. Escuriola‐Ettingshausen, W S Pipe,Peter Collins,Christophe Dhalluin,Gili Kenet,Christophe Schmitt,Muriel Buri, V. Jiménez,Flora Peyvandi,Guy Young, J. Oldenburg,Maria Elisa Mancuso,Anna Kiialainen,Tiffany Chang,Michaela Lehle, K Fijnvandraat

Hamostaseologie（2023）

引用 0|浏览8

暂无评分

摘要

Introduction Emicizumab (emi) prophylaxis can be started from haemophilia A (HA) diagnosis, reducing bleeding risk in infants with HA (IwHA). This interim analysis (IA) of HAVEN 7 (NCT04431726) evaluates the efficacy, safety and pharmacokinetics (PK) of emi in IwHA1.

查看译文

关键词

factor viii inhibitors,emicizumab prophylaxis,treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要